|
Two decades of prenatal diagnosis in hemophilia A and B: a systematic review of global trends and current practices |
2026 |
83 |
|
Neutrophil-Mediated Effects on Hemostasis and Thrombosis: Unraveling Their Complex Interaction in Thrombotic Events |
2026 |
82 |
|
In silico design of a novel therapeutic multi-epitope vaccine against NSCLC: a reverse vaccinology approach |
2026 |
81 |
|
Mild and Moderate Hemophilia A in Iran: A Clinical Spectrum and Molecular Insights from a Cohort of 110 Patients Including Novel F8 Variants |
2025 |
80 |
|
Molecular diagnosis of inherited platelet disorders: a tale of two realities – advanced vs. resource-limited setting |
2025 |
79 |
|
Genotyping R1336X and Eliminating the Pseudogene Amplification in Type 3 von Willebrand Disease Patients |
2025 |
78 |
|
HR9 cell-penetrating peptide: An effective delivery approach of gene editing vectors for tumor treatment |
2025 |
77 |
|
Advances in engineering immune–tumor microenvironments on-a-chip: integrative microfluidic platforms for immunotherapy and drug discovery |
2025 |
76 |
|
Investigation of the Potency of KALA and REV Cell-Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct |
2025 |
75 |
|
Immunoinformatics Analysis of Potent Therapeutic Formulations for the Development of HIV-1 Nefmut-Carrying Engineered Exosomes |
2025 |
74 |
|
Effective Plant-Derived Proteins and Peptides in Leukemia Treatment |
2025 |
73 |
|
Antitumor Effects of HPV E7 and L1-E7 Multiepitope DNA Constructs Delivered by Synthetic and Arginine-Rich Cell Penetrating Peptides |
2025 |
72 |
|
Minimum dataset for the development of the National Haemophilia Registry |
2025 |
71 |
|
Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study |
2024 |
70 |
|
Differential Immunostimulatory Effects of EGFP and +36 GFP on Immune Cells |
2024 |
69 |
|
Inhibition of HPV18 E6/E7 Protein-Expressing HeLa Cell Proliferation Using Optimized De Novo CRISPR/Cas9 Constructs Delivered by the LL-37 Peptide |
2024 |
68 |
|
Engineered ClearColi™-derived outer membrane vesicles as functional carriers for development of HIV-1 therapeutic vaccine candidate |
2024 |
67 |
|
Gynecological bleeding in women with congenital bleeding disorders: A comprehensive cohort from Iran |
2024 |
66 |
|
Impact of low-dose alendronate therapy on target joints in hemophilia patients in a low-income country |
2024 |
65 |
|
Genotype-phenotype analyses of Iranian patients with hemophilia B (Leyden-) and hemophilia B (Leyden+): A single-center study |
2024 |
64 |
|
Molecular and clinical profile of rare bleeding disorders: A single-center retrospective study |
2024 |
63 |
|
Natural Anticoagulant Protein Levels in Patients With Beta-Thalassemia Major: A Case-Control Study |
2024 |
62 |
|
Falsely prolonged prothrombin time test in a patient with erythrocytosis: a case report |
2024 |
61 |
|
Successful Expression of DNA-Based Vaccine Construct Encoding Human Papillomavirus Type 16 E7 Fused to Heat Shock Protein B1 in Eukaryotic Cells |
2023 |
60 |
|
Comparison of Adjuvant Effects of Montanide ISA-720 and Heat Shock Protein 27 in Increasing Immunostimulatory Properties of HIV-1 Nef-Vif Fusion Protein Construct |
2023 |
59 |
|
Evaluation of MALAT-1 and HOTAIR LncRNAs Expression Levels in Incidence of Hemophilia |
2023 |
58 |
|
LL-37 antimicrobial peptide and heterologous prime-boost vaccination regimen significantly induce HIV-1 Nef-Vpr antigen- and virion-specific immune responses in mice |
2023 |
57 |
|
Congenital Factor V Deficiency, Diagnosis, and Management |
2023 |
56 |
|
Associations of multiple genetic variations with plasma levels of Von Willebrand Factor and clinical phenotype in Iranian patients with Von Willebrand disease type 1 |
2023 |
55 |
|
Bleeding disorder of unknown cause: Results from Iranian study |
2023 |
54 |
|
Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review |
2023 |
53 |
|
Molecular basis of rare congenital bleeding disorders |
2023 |
52 |
|
Protein S Deficiency with Two Novel PROS1 Gene Variants |
2023 |
51 |
|
Different dendritic cells-based vaccine constructs influence HIV-1 antigen-specific immunological responses and cytokine generation in virion-exposed splenocytes |
2022 |
50 |
|
Immunopotentiation by linking Hsp70 T-cell epitopes to Gag-Pol-Env-Nef-Rev multiepitope construct and increased IFN-gamma secretion in infected lymphocytes |
2022 |
49 |
|
Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen |
2022 |
48 |
|
Genotypes and phenotypes characterization of 17 Iranian patients with inherited factor X deficiency: identification of a novel mutation: Leu487Phe |
2022 |
47 |
|
Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells. |
2021 |
46 |
|
Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays |
2021 |
45 |
|
Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study |
2021 |
44 |
|
Inhibitor development in patients with type 3 Von Willebrand disease, a comprehensive study on 99 Iranian patients. |
2021 |
43 |
|
Challenges and concerns of patients with congenital bleeding disorders affected by coronavirus disease 2019 |
2021 |
42 |
|
Persistent hiccups in a patient with mild congenital factor V deficiency and COVID‐19; clinical and laboratory finding of a rare bleeding disorder |
2021 |
41 |
|
Congenital combined bleeding disorders, a comprehensive study of a large number of Iranian patients |
2021 |
40 |
|
Do congenital bleeding disorders have a protective effect against COVID-19? A prospective study |
2021 |
39 |
|
Correlation of SARS-CoV-2 infection with hepatitis and liver disorders |
2021 |
38 |
|
Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders |
2021 |
37 |
|
HIV-1 Accessory Proteins: Which one is Potentially Effective in Diagnosis and Vaccine Development? |
2021 |
36 |
|
Antimicrobial/ anticancer peptides: bioactive molecules and therapeutic agents |
2021 |
35 |
|
The next generation of HCV vaccines: a focus on novel adjuvant development |
2021 |
34 |
|
In silico design and in vitro expression of novel multiepitope DNA constructs based on HIV-1 proteins and Hsp70 T-cell epitopes |
2021 |
33 |
|
Expression of a novel HIV-1 Gag-Pol-Env-Nef-Rev multi-epitope construct in Escherichia coli |
2021 |
32 |
|
Detection of Anti-IgGs against Heat Shock Proteins 27 and 20, HP91 Peptide, and HIV-1 Polypeptides in HIV-Positive and Negative Patients |
2020 |
31 |
|
Pharmaceutical approaches for treatment of hepatitis C virus |
2020 |
30 |
|
Small interfering RNAs and their delivery systems: A novel powerful tool for the potential treatment of HIV infections |
2020 |
29 |
|
Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents |
2020 |
28 |
|
Impact of Blood Transfusion on the Prevalence of HHpgV-1, HPgV-1, and B19V Among Iranian HCV-infected Patients With Hemophilia |
2020 |
27 |
|
B1 protein: a novel cell penetrating protein for in vitro and in vivo delivery of HIV-1 multi-epitope DNA constructs |
2020 |
26 |
|
Genotyping of intron 1 and 22 inversion of factor VIII gene using IS-PCR in Kurdish patients of Iraq |
2020 |
25 |
|
Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C |
2020 |
24 |
|
Design of novel multiepitope constructs based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis |
2020 |
23 |
|
An overview of in silico vaccine design against different pathogens and cancer |
2020 |
22 |
|
Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools |
2020 |
21 |
|
Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses |
2020 |
20 |
|
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID‐19—A common clinical feature between a rare disorder and a new, common infection. |
2020 |
19 |
|
Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of rare coagulation factor deficiencies besides hemophilia |
2020 |
18 |
|
First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan. |
2019 |
17 |
|
Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia. |
2019 |
16 |
|
Heat shock proteins in infection |
2019 |
15 |
|
Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions |
2019 |
14 |
|
Anti-viral effects of super positively charged mutant of green fluorescent protein |
2019 |
13 |
|
Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors? |
2019 |
12 |
|
Analysis of long non-coding RNA expression in hemophilia A patients |
2019 |
11 |
|
Inflammatory and immune response genes: A genetic analysis of inhibitor development in Iranian hemophilia A patients |
2019 |
10 |
|
In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. |
2019 |
9 |
|
Expression of the Neuron-Related Genes in hNGF-β-Treated PC12 Cells |
2018 |
8 |
|
Polymorphisms in the TGF-β1 (rs1982037) and IL-2 (rs2069762, rs4833248) genes are not associated with inhibitor development in Iranian patients with hemophilia A |
2018 |
7 |
|
Polymorphism analysis of the CTLA-4 (rs231775) gene as a marker of inhibitor development in Iranian patients with hemophilia A |
2018 |
6 |
|
Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected patients with Hemophilia Treated with Direct-Acting Antiviral Agents |
2018 |
5 |
|
Prediction of cross-clade HIV-1 T-cell epitopes using immunoinformatics analysis |
2018 |
4 |
|
Investigating the IGSF2 and TNFα Genes Polymorphism and the Risk of Inhibitor Development in Patients with Hemophilia A |
2017 |
3 |
|
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. |
2016 |
2 |
|
Physicochemical properties of polymers: An important system to overcome the cell barriers in gene transfection. |
2015 |
1 |